Evogene Ltd. (NASDAQ:EVGN) Short Interest Up 154.6% in June

Evogene Ltd. (NASDAQ:EVGN) was the recipient of a large growth in short interest during the month of June. As of June 15th, there was short interest totaling 313,620 shares, a growth of 154.6% from the May 31st total of 123,199 shares. Based on an average daily volume of 2,420,901 shares, the short-interest ratio is currently 0.1 days. Currently, 3.9% of the shares of the stock are sold short.

Evogene Stock Up 1.1%

NASDAQ:EVGN opened at $0.39 on Monday. The firm has a market cap of $3.43 million, a PE ratio of -0.28 and a beta of 1.35. Evogene has a 12 month low of $0.37 and a 12 month high of $1.50. The company’s 50-day moving average price is $0.67 and its two-hundred day moving average price is $0.85.

Evogene (NASDAQ:EVGN) last posted its quarterly earnings data on Saturday, May 16th. The biotechnology company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.33). The firm had revenue of $0.33 million for the quarter, compared to analyst estimates of $0.35 million. Evogene had a negative return on equity of 158.82% and a negative net margin of 638.12%.

Institutional Investors Weigh In On Evogene

Large investors have recently bought and sold shares of the business. Jane Street Group LLC increased its holdings in Evogene by 58.0% during the 1st quarter. Jane Street Group LLC now owns 33,732 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 12,387 shares in the last quarter. Citadel Advisors LLC raised its position in Evogene by 169.4% in the 3rd quarter. Citadel Advisors LLC now owns 57,575 shares of the biotechnology company’s stock valued at $66,000 after purchasing an additional 36,206 shares during the last quarter. Finally, XTX Topco Ltd bought a new position in Evogene in the 4th quarter valued at $25,000. 10.40% of the stock is currently owned by institutional investors.

About Evogene

Evogene Ltd. is a biotechnology company specializing in the use of computational and predictive biology technologies to design and develop novel products for agriculture and human health. Founded in 2002 and headquartered in Rehovot, Israel, the company has built a proprietary computational platform that integrates genomics, machine learning and data analytics to identify gene targets and biological traits. Evogene’s platform serves as the backbone for its research and development efforts, enabling the discovery of enhanced crop traits, microbial solutions and microbiome-based diagnostics and therapeutics.

In the agricultural sector, Evogene applies its platform to improve crop performance across a range of parameters, including yield enhancement, stress tolerance and resistance to pests and pathogens.